Stock Events

Oramed Pharmaceuticals 

ILA920
48
+ILA0+0% Today

Statistics

Day High
920
Day Low
915
52W High
920
52W Low
6.61
Volume
1,804
Avg. Volume
18,673
Mkt Cap
1.36M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.26
-0.06
0.13
0.33
Expected EPS
0.02
Actual EPS
0.33

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ORMP.TA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap482.65B
Novo Nordisk is a leading global healthcare company that develops diabetes care products, directly competing with Oramed's oral insulin capsule.
Mannkind
MNKD
Mkt Cap1.4B
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for diabetes, such as Afrezza, competing in the diabetes management space.
Sanofi
SNY
Mkt Cap125.78B
Sanofi is a multinational pharmaceutical company that offers a range of diabetes solutions, including insulin products, competing in the same therapeutic area as Oramed.
Lilly(Eli) &
LLY
Mkt Cap869.21B
Eli Lilly and Company is a global healthcare leader that develops a wide range of pharmaceutical products, including treatments for diabetes, directly competing with Oramed's products.
Astrazeneca
AZN
Mkt Cap239.79B
AstraZeneca is a global, science-led biopharmaceutical business that has a significant portfolio of diabetes treatments, competing in the same market as Oramed.
Bristol-Myers Squibb
BMY
Mkt Cap80.39B
Bristol-Myers Squibb is a global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines, including for diabetes, which puts it in competition with Oramed.
Merck &
MRK
Mkt Cap320.27B
Merck & Co., Inc. offers a broad range of diabetes treatments, including oral medications, directly competing with Oramed's oral insulin product.
Tandem Diabetes Care
TNDM
Mkt Cap2.61B
Tandem Diabetes Care, Inc. designs, develops, and commercializes products for people with insulin-dependent diabetes, competing in the broader diabetes care market.
Insulet
PODD
Mkt Cap13.79B
Insulet Corporation is engaged in the development, manufacture, and sale of its Omnipod Insulin Management System, a competitor in the insulin delivery space.
Dexcom
DXCM
Mkt Cap45.21B
DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems for diabetes management, indirectly competing by offering alternative diabetes management solutions.

About

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Show more...
CEO
Mr. Nadav Kidron Esq.
Country
United States
ISIN
US68403P2039
WKN
000A1CTNU

Listings